All Stories

  1. Global multi-stakeholder endorsement of the MAFLD definition
  2. Chronic liver diseases must be reduced worldwide: it is time to act
  3. Seroprevalence and risk factors of hepatitis B, C and D virus infection amongst patients with features of hepatitis in a referral hospital in Botswana: A cross-sectional study
  4. Prevalence of liver fibrosis using transient elastography in the general population in Cambodia: a pilot study
  5. Case Report: First Two Identified Cases of Fabry Disease in Central Asia
  6. Violence Against Healthcare Workers: A Worldwide Phenomenon With Serious Consequences
  7. Acute liver failure
  8. Commentary: Systemic Lupus Erythematosus in Native sub-Saharan Africans: A Systematic Review and Meta-Analysis
  9. HIV and SARS-Coronavirus-2 Epidemics: Possible Interactions and Need for Studies, Especially in Africa
  10. Alcohol? Not for Non-alcoholic Fatty Liver Disease Patients
  11. Portal Vein Thrombosis in a 21-Year-Old Man with Membranoproliferative Glomerulonephritis and Nephrotic Syndrome
  12. Everyday ethical challenges of nurse-physician collaboration
  13. Orphan drugs
  14. Khat-related liver disease in sub-Saharan Africa: neglected, yet important – Authors' reply
  15. Defensive medicine: It is time to finally slow down an epidemic
  16. Liver cirrhosis in sub-Saharan Africa: neglected, yet important
  17. Detection of Hepatitis E Antibodies in Kazakhstan: A Pilot Study
  18. End-stage liver disease in eastern Europe and central Asia: action is needed
  19. Treatment of Acute Liver Failure in Resource-Constrained Settings without Transplantation Facilities Can Be Improved
  20. Liver diseases in sub-Saharan Africa: the importance of dedicated public clinics
  21. Liver disease in patients with HIV in sub-Saharan Africa
  22. AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial
  23. Management of chronic hepatitis B in children: An unresolved issue
  24. Limited Adherence to Antiretroviral Regimens in an Italian Cohort
  25. Can HIV-1 viral interference be used therapeutically?
  26. Hepatitis C virus and human immunodeficiency virus transmission routes: Differences and similarities
  27. Dose reduction of antiretrovirals: a feasible and testable approach to expand HIV treatment in developing countries
  28. Liver diseases in developing countries
  29. A Return to the Past: The Vital Importance of Autopsies for Infectious Disease Practice in 2011
  30. Silica Exposure and Silicosis: Action is Needed Now
  31. Antiretroviral therapy in low-resource settings
  32. Time for universal HIV and HBV screening for patients with cancer
  33. The challenge of lymphomas in sub-Saharan Africa
  34. Lymph nodes and pathogenesis of infection with HIV-1
  35. The need for new antibiotics
  36. Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
  37. Viral Encephalitis: Etiology, Clinical Features, Diagnosis and Management
  38. Perspectives in therapy for hepatitis C
  39. Lung infections after cancer chemotherapy
  40. Hepatitis C Virus Infection in the Elderly
  41. Autoimmune sclerosing cholangitis in two sisters
  42. Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults
  43. Infections and thalassaemia
  44. Clinical course of infection with hepatitis C
  45. Human Immunodeficiency Virus-Associated Peripheral Neuropathies
  46. Interleukin-2 therapy and CD4+ T cells in HIV-1 infection
  47. CHILDHOOD HEPATITIS C VIRUS INFECTION.
  48. Tipranavir
  49. Antinuclear antibodies are common in an infectious environment but do not predict systemic lupus erythematosus
  50. Can We Really Identify HIV-1 Long-Term Nonprogressors?
  51. Initial antiretroviral therapy in chronically-infected HIV-positive adults
  52. Is there a role for viruses in triggering autoimmune hepatitis?
  53. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment
  54. Sequelae and Serologic Outcome in Persons with Hepatitis B Virus Infection
  55. Erratum
  56. Infections and solid organ transplant rejection: a cause-and-effect relationship?
  57. Long-term efficacy of dual nucleoside reverse transcriptase inhibitor antiretroviral therapy in HIV-1 infection
  58. Hepatitis C is not a sexually transmissible disease
  59. Treatment of autoantibody-associated chronic hepatitis C
  60. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue
  61. Childhood Infections and Autoimmune Diseases
  62. Does hepatitis C virus cause severe liver disease only in people who drink alcohol?
  63. Full Adherence to HAART: Is It Really Necessary?
  64. BCG efficacy and tuberculin skin testing
  65. Hepatotoxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV
  66. A Case of Visceral Leishmaniasis with Protracted Incubation in a Nonendemic Area
  67. Mortality Due to Hepatitis C Virus–Related Cirrhosis in Patients Infected with HIV Type 1: A Role for Alcohol
  68. MHC Class I Molecules and Progression to AIDS
  69. Hepatitis A Virus Infection and Atherosclerosis
  70. No Increase in Liver Decompensation Risk with Atypical Hepatitis C Virus Antibody Pattern
  71. Failure of lamivudine therapy for chemotherapy-induced reactivation of Hepatitis B
  72. HIV-1 progression in hepatitis-C-infected drug users
  73. Effect of pregnancy on chronic hepatitis C
  74. Cryptococcal meningitis during cyclosporin treatment in a patient with psoriasis
  75. Coxsackie B virus-induced autoimmunity to GAD does not lead to type 1 diabetes
  76. Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C
  77. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance
  78. Steroid and interferon therapy in liver/kidney microsomal antibody-positive patients with chronic hepatitis C
  79. Resolution of autoimmune hepatitis after bone-marrow transplantation
  80. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus
  81. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals